Synonym
HS-731; HS731; HS 731;
IUPAC/Chemical Name
((4R,4aS,7R,7aR,12bS)-9-hydroxy-4a-methoxy-3-methyl-2,3,4,4a,5,6,7,7a-octahydro-1H-4,12-methanobenzofuro[3,2-e]isoquinolin-7-yl)glycine
InChi Key
YHKUQEWICWSOTO-SWJKATBISA-N
InChi Code
InChI=1S/C20H26N2O5/c1-22-8-7-19-16-11-3-4-13(23)17(16)27-18(19)12(21-10-15(24)25)5-6-20(19,26-2)14(22)9-11/h3-4,12,14,18,21,23H,5-10H2,1-2H3,(H,24,25)/t12-,14-,18+,19+,20-/m1/s1
SMILES Code
OC1=CC=C2C3=C1O[C@@H]([C@H](NCC(O)=O)CC4)[C@@]3(CCN5C)[C@]4(OC)[C@H]5C2
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
To be determined
Shelf Life
>2 years if stored properly
Drug Formulation
To be determined
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
Preparing Stock Solutions
The following data is based on the
product
molecular weight
374.44
Batch specific molecular weights may vary
from batch to batch
due to the degree of hydration, which will
affect the solvent
volumes required to prepare stock solutions.
| Concentration / Solvent Volume / Mass |
1 mg |
5 mg |
10 mg |
| 1 mM |
1.15 mL |
5.76 mL |
11.51 mL |
| 5 mM |
0.23 mL |
1.15 mL |
2.3 mL |
| 10 mM |
0.12 mL |
0.58 mL |
1.15 mL |
| 50 mM |
0.02 mL |
0.12 mL |
0.23 mL |
1: Puls K, Schmidhammer H, Wolber G, Spetea M. Mechanistic Characterization of the Pharmacological Profile of HS-731, a Peripherally Acting Opioid Analgesic, at the µ-, δ-, κ-Opioid and Nociceptin Receptors. Molecules. 2022 Jan 28;27(3):919. doi: 10.3390/molecules27030919. PMID: 35164182; PMCID: PMC8840597.
2: Baillie LD, Schmidhammer H, Mulligan SJ. Peripheral μ-opioid receptor mediated inhibition of calcium signaling and action potential-evoked calcium fluorescent transients in primary afferent CGRP nociceptive terminals. Neuropharmacology. 2015 Jun;93:267-73. doi: 10.1016/j.neuropharm.2015.02.011. Epub 2015 Feb 24. PMID: 25721395.
3: Al-Khrasani M, Spetea M, Friedmann T, Riba P, Király K, Schmidhammer H, Furst S. DAMGO and 6beta-glycine substituted 14-O-methyloxymorphone but not morphine show peripheral, preemptive antinociception after systemic administration in a mouse visceral pain model and high intrinsic efficacy in the isolated rat vas deferens. Brain Res Bull. 2007 Oct 19;74(5):369-75. doi: 10.1016/j.brainresbull.2007.07.008. Epub 2007 Jul 30. PMID: 17845912.
4: Morokata T, Suzuki K, Masunaga Y, Taguchi K, Morihira K, Sato I, Fujii M, Takizawa S, Torii Y, Yamamoto N, Kaneko M, Yamada T, Takahashi K, Shimizu Y. A novel, selective, and orally available antagonist for CC chemokine receptor 3. J Pharmacol Exp Ther. 2006 Apr;317(1):244-50. doi: 10.1124/jpet.105.097048. Epub 2005 Dec 9. PMID: 16339911.
5: Bileviciute-Ljungar I, Spetea M, Guo Y, Schütz J, Windisch P, Schmidhammer H. Peripherally mediated antinociception of the mu-opioid receptor agonist 2-[(4,5alpha-epoxy-3-hydroxy-14beta-methoxy-17-methylmorphinan-6beta- yl)amino]acetic acid (HS-731) after subcutaneous and oral administration in rats with carrageenan-induced hindpaw inflammation. J Pharmacol Exp Ther. 2006 Apr;317(1):220-7. doi: 10.1124/jpet.105.096032. Epub 2005 Dec 8. PMID: 16339394.
